Royce & Associates LP Vir Biotechnology, Inc. Transaction History

Royce & Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$9.14 - $24.62 $44,996 - $121,204	-4,923 Reduced 4.57%	102,900 $964,000
Q2 2023 Aug 07, 2023	BUY	$23.2 - $27.29 $1.31 Million - $1.54 Million	56,516 Added 110.15%	107,823 $2.64 Million
Q1 2023 May 04, 2023	SELL	$22.26 - $30.85 $124,566 - $172,636	-5,596 Reduced 9.83%	51,307 $1.19 Million
Q4 2022 May 23, 2023	BUY	$19.96 - $28.22 $111,696 - $157,919	5,596 Added 10.91%	56,903 $1.44 Million
Q4 2022 Feb 13, 2023	BUY	$19.96 - $28.22 $570,756 - $806,950	28,595 Added 101.01%	56,903 $1.44 Million
Q3 2022 Nov 03, 2022	BUY	$18.26 - $31.1 $516,904 - $880,378	28,308 New	28,308 $546,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $979M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.